VTRS - Viatris
12.52
| Index: | S&P 500 | P/E: | - | EPS (ttm): | -0.74 | Insider Own: | 2.44% | Shs Outstand: | 1.19B | Perf Week: | -0.87% |
| Market Cap: | 15.42B | Forward P/E: | 4.73 | EPS next Y: | 2.65 | Insider Trans: | -2.03% | Shs Float: | 1.16B | Perf Month: | -4.65% |
| Income(ttm): | -883.30M | PEG: | - | EPS next Q: | 0.58 | Inst Own: | 79.62% | Short Float: | 1.77% | Perf Quarter: | 9.15% |
| Revenue(ttm): | 15.03B | P/S: | 1.03 | EPS this Y: | -8.50% | Inst Trans: | -2.23% | Short Ratio: | 2.65 | Perf Half Y: | 19.58% |
| Book/sh: | 16.58 | P/B: | 0.76 | EPS next Y: | -1.37% | ROA: | -1.89% | Short Interest: | 20.60M | Perf Year: | 19.81% |
| Cash/sh: | 1.60 | P/C: | 7.81 | EPS next 5Y: | -3.41% | ROE: | -4.35% | 52W Range: | 9.93 - 13.62 | Perf YTD: | 15.60% |
| Dividend Est.: | - | P/FCF: | 7.92 | EPS past 5Y: | -41.87% | ROI: | -2.58% | 52W High: | -8.06% | Beta: | 0.96 |
| Dividend TTM: | 0.48 (3.83%) | Quick Ratio: | 0.88 | Sales past 5Y: | 7.93% | Gross Margin: | 40.92% | 52W Low: | 26.15% | ATR (14): | 0.33 |
| Dividend Ex-Date: | Nov 22, 2024 | Current Ratio: | 1.43 | EPS Y/Y TTM: | -148.59% | Oper. Margin: | 9.48% | RSI (14): | 47.73 | Volatility: | 2.84% 2.38% |
| Employees: | 38000 | Debt/Eq: | 0.81 | Sales Y/Y TTM: | -2.55% | Profit Margin: | -5.88% | Recom: | 3.10 | Target Price: | 13.17 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.73 | EPS Q/Q: | -71.23% | Payout: | 1059.60% | Rel Volume: | 7.25 | Prev Close: | 12.13 |
| Sales Surprise: | 0.96% | EPS Surprise: | 10.82% | Sales Q/Q: | -4.30% | Earnings: | Nov 07 BMO | Avg Volume: | 7.78M | Price: | 12.52 |
| SMA20: | -2.38% | SMA50: | 0.90% | SMA200: | 7.70% | Undervalued: 5.19% | Volume: | 56,375,690 | Change: | 3.22% | |
Graham Classic formula value: -1.12
(P/E=8 * 1g) Min value: -3.05
(current P/E * 2g) Max value: 4.53
Average value: 0.12
Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.